Genoway licenses CRISPR/Cas9 tech from ERS Genomics

By The Science Advisory Board staff writers

French company Genoway has entered a nonexclusive license agreement with ERS Genomics that grants Genoway past and future access to ERS Genomics' CRISPR/Cas9 patent portfolio.

Genoway is focused on the development of genetically engineered preclinical research models, specifically modified mice, rat, and cell lines. The license will allow the company to broaden its rodent model offerings.

Financial details of the agreement were not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?